Latest News
Web Date: February 3, 2017

Polymer improves stability of protein drug

A trehalose-based glycopolymer protects insulin against heat and mechanical stress, prolonging the protein’s in vivo lifetime in mice
Department: Science & Technology
News Channels: Biological SCENE
Keywords: biologics, trehalose, glycopolymer, protein drug, insulin, stabilization, conjugate
A glycopolymer with trehalose sidechains increases the in vivo lifetime of insulin in mice and safeguards the protein from heat and mechanical stress that could arise during storage and transport.
Credit: Bioconjugate Chem.
Structure of trehalose glycopolymer conjugated to insulin
A glycopolymer with trehalose sidechains increases the in vivo lifetime of insulin in mice and safeguards the protein from heat and mechanical stress that could arise during storage and transport.
Credit: Bioconjugate Chem.

Attaching biocompatible polymers like polyethylene glycol (PEG) to therapeutic proteins can prolong their lifetime in the bloodstream. But many of these polymers don’t stabilize protein drugs outside the body. Protein drugs often require refrigeration and careful handling during storage and transport; otherwise, they can become inactive, with life-threatening consequences for patients.

Now, researchers have developed a polymer that could stabilize protein drugs both before and after injection. When attached to insulin, the glycopolymer, whose sidechains contain the disaccharide trehalose, prolonged the protein’s lifetime in mice without toxic effects. It also prevented insulin from aggregating in a test tube when exposed to heat and mechanical stress, conditions that can occur during handling and shipping (Bioconjugate Chem. 2017, DOI: 10.1021/acs.bioconjchem.6b00659).

Heather D. Maynard of the University of California, Los Angeles, and colleagues had already found that the trehalose glycopolymer could protect lysozyme and other enzymes from heat and freeze-drying. In the new study, they wanted to test the glycopolymer’s ability to stabilize protein drugs in and out of the body. They focused on insulin, widely used to regulate blood glucose levels in people with diabetes.

After finding that the glycopolymer protected insulin from heat, mechanical stress, and aggregation, even when the two components were simply combined in a tube, the team tested insulin-glycopolymer conjugates, attaching two glycopolymer chains to the protein at different sites. The conjugate turned out to be just as stable as the insulin-glycopolymer mixture when exposed to the same heat and agitation tests.

Injected into mice, the insulin-glycopolymer conjugate had about the same lifetime as an insulin-PEG conjugate—a combination known to increase the lifetime of insulin in vivo. The insulin-glycopolymer conjugate lowered blood glucose levels in mice but required a fivefold higher dose than insulin alone. Earlier studies had reported similar results with insulin-PEG, possibly because the polymer blocks insulin from binding to its receptor. Future research could identify glycopolymers to conjugate to the insulin protein that better enable receptor binding, according to the researchers.

“This is a promising alternative to PEG,” the staple polymer conjugated to protein drugs, says Theresa M. Reineke of the University of Minnesota. Maynard has already begun testing the trehalose glycopolymer with other therapeutic proteins. Stabilizing these drugs is important in the U.S., she says, but also in other areas where continuous refrigeration isn’t available. Still, longer-term preclinical studies are needed. “In-depth mechanistic studies are probably warranted in a future study, as well, to fully understand this system,” Reineke says.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society
Russ Lehrman (Wed Feb 08 21:35:25 EST 2017)
Great study! How large is the polymer? Is the loss of bioactivity due to polymer size or the point of attachment? If they haven't already, these researchers may want to take a reactive form of trehalose monomer, conjugate to insulin as they've done in this study, and assess bioactivity of the modified insulin. Since the non-conjugated mixture also protects insulin from aggregation, they may want to continue to assess the trehalose glycopolymer v trehalose as a potential excipient. Establishing new non-toxic excipients that can be used to create novel drug products is most welcome!
Heather Maynard (Tue Apr 25 14:44:55 EDT 2017)
Thank you for the kind comments. The conjugated polymer was 10 kDa. We believe the loss of bioactivity is mostly due to the conjugation at the GlyA1 residue, which is involved in receptor binding. With regard to comparison to trehalose itself, we have consistently observed in our previous studies with other proteins (see J. Am. Chem. Soc. 2012, DOI: 10.1021/ja2120234, Biomacromolecules 2013, DOI: 10.1021/bm4003046) that the trehalose glycopolymer stabilizes better than trehalose alone as an excipient, so we expected a similar result with insulin stabilization. After the publication, we compared insulin stabilization with the polymer or with small molecule trehalose, and the polymer indeed stabilizes better than the free sugar itself added at 50 weight equivalents.
Tyler (Tue Feb 14 10:26:53 EST 2017)
I assume you predict that your conjugation point is on the lysine residues of the protein. How did you prove that the polymer is conjugating rather than simply ionically coating the protein? I've tried to test the presence of a covalent reaction using lysine and PEG with a microcalorimeter but was unable to resolve such a small reaction with my instrumentation. What are you proposing is the reaction mechanism occurring between the polymer and protein and how could you go about proving it?
- Tyler
Undergraduate, University of Georgia
Leave A Comment